RNAZ TransCode Therapeutics, Inc.

$3.28

TransCode Therapeutics, Inc. (RNAZ) is expected to report earnings on November 13, 2026, after the market close.

TransCode Therapeutics Reported Earnings
Earnings Date
Nov 13
Friday · 7:25 PM ET
Earnings Whisper
-
vs -
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP -

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About TransCode Therapeutics, Inc.

TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON.